TPH1
Tryptophan 5-hydroxylase 1
Also known as: TPH, TPH1_HUMAN, TPRH
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- P17752
- Gene
- TPH1
- Ensembl
- ENSG00000129167
- Chromosome
- 11
- Canonical length
- 444 aa
- Protein class
- Enzymes, FDA approved drug targets, Metabolic proteins, Predicted intracellular proteins
- Subcellular location
- Cytosol
- Quaternary structure
- Homotetramer
OverviewNCBI Gene
This gene encodes a member of the aromatic amino acid hydroxylase family. The encoded protein catalyzes the first and rate limiting step in the biosynthesis of serotonin, an important hormone and neurotransmitter. Mutations in this gene have been associated with an elevated risk for a variety of diseases and disorders, including schizophrenia, somatic anxiety, anger-related traits, bipolar disorder, suicidal behavior, addictions, and others.[provided by RefSeq, Apr 2009]
Canonical amino-acid sequenceUniProt
444 residues, UniProt reviewed canonical sequence.
>P17752|TPH1
1 MIEDNKENKD HSLERGRASL IFSLKNEVGG LIKALKIFQE KHVNLLHIES RKSKRRNSEF
61 EIFVDCDINR EQLNDIFHLL KSHTNVLSVN LPDNFTLKED GMETVPWFPK KISDLDHCAN
121 RVLMYGSELD ADHPGFKDNV YRKRRKYFAD LAMNYKHGDP IPKVEFTEEE IKTWGTVFQE
181 LNKLYPTHAC REYLKNLPLL SKYCGYREDN IPQLEDVSNF LKERTGFSIR PVAGYLSPRD
241 FLSGLAFRVF HCTQYVRHSS DPFYTPEPDT CHELLGHVPL LAEPSFAQFS QEIGLASLGA
301 SEEAVQKLAT CYFFTVEFGL CKQDGQLRVF GAGLLSSISE LKHALSGHAK VKPFDPKITC
361 KQECLITTFQ DVYFVSESFE DAKEKMREFT KTIKRPFGVK YNPYTRSIQI LKDTKSITSA
421 MNELQHDLDV VSDALAKVSR KPSILocalizationUniProt · AlphaFold · HPA
Whether an antibody against TPH1 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Intracellular
- Secreted
- No
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.27
- Highest tissue expression
- 19 nTPM
Expression across tissuesHPA
Tissue
- rectum: 19 nTPM
- stomach: 15 nTPM
- small intestine: 11 nTPM
- duodenum: 9.8 nTPM
- colon: 8.7 nTPM
- choroid plexus: 6.4 nTPM
Single-cell type
- neuroendocrine cells: 570 nCPM
- gonadotrophs: 44 nCPM
- retinal bipolar cells: 9.5 nCPM
- parietal cells: 7.1 nCPM
- oligodendrocytes: 6.5 nCPM
- thyrotrophs: 5.3 nCPM
Immune cell
- basophil: 0.3 nTPM
- gdT-cell: 0.2 nTPM
- naive B-cell: 0.2 nTPM
- neutrophil: 0.2 nTPM
- MAIT T-cell: 0.1 nTPM
- NK-cell: 0.1 nTPM
Brain region
- midbrain: 23 nTPM
- choroid plexus: 12 nTPM
- hypothalamus: 8 nTPM
- pons: 3.7 nTPM
- hippocampal formation: 2 nTPM
- thalamus: 2 nTPM
DiseaseUniProt · ClinVar · IEDB · PubMed
Four sources answering four different questions about TPH1.
Disease | AutoantibodyPubMed
Conditions in which antibodies against TPH1 are reported. Each links to that disease's full target list.
ReferencesPubMed · IEDB
Publications for TPH1 from three distinct lines of evidence, kept separate because they answer different questions: whether antibodies are directed at the protein, whether a B-cell epitope has been mapped on it, and whether a T-cell epitope has. Each is labelled with its source.
Reference: AutoantibodyPubMed
3 publications
- Disease specificity of anti-tryptophan hydroxylase-1 and anti-AIE-75 autoantibodies in APECED and IPEX syndrome.
2015 · Clin Immunol · RCR 0.9 · 25 citations - Gastrointestinal immunity against tryptophan hydroxylase-1, aromatic L-amino-acid decarboxylase, AIE-75, villin and Paneth cells in APECED.
2015 · Clin Immunol · RCR 0.5 · 15 citations - Autoantibodies against aromatic amino acid hydroxylases in patients with autoimmune polyendocrine syndrome type 1 target multiple antigenic determinants and reveal regulatory regions crucial for enzymatic activity.
2013 · Immunobiology · RCR 0.2 · 8 citations
Sources: PubMed — antigen-level antibody evidence from a custom retrieval. Records matching a controlled set of autoantibody terms (the MeSH descriptors Autoantibodies and Autoantigens, with title and abstract term variants) were obtained through NCBI E-utilities, and their titles and abstracts parsed for constructions that direct an antibody at a named protein rather than for co-occurrence. Captured names were resolved against UniProt nomenclature and each antigen adjudicated individually against the source text. Bibliographic records from PubMed and MeSH, U.S. National Library of Medicine; citation metrics from NIH iCite (Hutchins et al., PLoS Biology 2016). Titles link to PubMed; abstracts are not reproduced here. The NLM does not endorse this analysis.
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 0.93
- gnomAD pLI
- 0
- gnomAD missense Z
- 0.73
- DepMap mean gene effect
- -0.08
- DepMap dependency class
- selective
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 2% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- bone remodeling
- mammary gland alveolus development
- platelet degranulation
- positive regulation of fat cell differentiation
- serotonin biosynthetic process
- regulation of hemostasis
- serotonin biosynthetic process from tryptophan
Molecular functions
Cellular components
Protein domainsUniProt · Pfam · InterPro
- Aromatic amino acid hydroxylase
- ACT domain
- Tryptophan 5-monooxygenase
- Aromatic amino acid hydroxylase, iron/copper binding site
- Tyrosine 3-monooxygenase-like
- Aromatic amino acid hydroxylase, C-terminal
- Aromatic amino acid monoxygenase, C-terminal domain superfamily
- Aromatic amino acid hydroxylase superfamily
- Tryptophan 5-hydroxylase, catalytic domain
- ACT-like domain
- Biopterin-dependent aromatic amino acid hydroxylase
KeywordsUniProt
InteractionsUniProt · HPA
Protein binding partners of TPH1 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads TPH1 as an antibody target. Whether an autoantibody or antibody against TPH1 could matter depends on whether native TPH1 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
TPH1 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.
Annotation status
The present source text does not explicitly label TPH1 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...